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GENERAL CONSIDERATIONS OF
CARDIAC ARREST RISK AMONG ATHLETES
The incidence of out-of-hospital cardiac arrest among the
general population of adults is 1 to 2 deaths per 1,000
subjects per year; a figure that represents 50% of all
cardiovascular deaths (1). For the adolescent and young
adult subgroups, the estimated incidence is 1 per 100,000
per year or less. Available data suggest that among the
younger population, competitive athletes account for a
disproportionately higher-risk subset, compared to the gen-
eral population in a comparable age group (2–4). In
addition, among the adult population performing condi-
tioning activities in health clubs, the probability of cardiac
arrest during exertion appears higher than the expected rate
for comparable groups generally, especially among persons
who exercise despite being habitually sedentary (5).
Within the subgroup of the population age 35 years and
older, coronary heart disease accounts for approximately
80% of all sudden cardiac deaths (SCDs), with the cardio-
myopathies accounting for another 10% to 15%. In the
younger age groups, hypertrophic cardiomyopathy, anoma-
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lous coronary arteries, myocarditis, and various other inher-
ited disorders that are associated with arrhythmic risk
dominate the etiologies (1). Although the absolute risk for
the young athlete remains low, the excess compared to the
general population in their age group and the life expectancy
associated with the underlying diseases in the absence of a
cardiac arrest, suggests the need for aggressive approaches to
the recognition of individuals at risk, and for systems to
respond to unexpected events.
ROLE OF AUTOMATED EXTERNAL
DEFIBRILLATORS IN RESPONSE TO CARDIAC ARREST
In attacking the problem of SCD, it is unrealistic to assume
that any single approach—epidemiological surveillance, pri-
mary prevention of disease states, clinical interventions of
established diseases, or community-based response sys-
tems—will have a major impact alone. Each strategy has a
role, in part because a large majority of events occur
unexpectedly in the out-of-hospital environment and are
not predictable with great accuracy by risk profiling in most
clinical circumstances (6).
Because the majority of out-of-hospital cardiac arrests
occur by the initial mechanism of ventricular fibrillation,
community-based defibrillation strategies have emerged as
one approach to the SCD problem. Time to defibrillation is
the most important factor in survival from out-of-hospital
cardiac arrest due to ventricular fibrillation (7). Thus,
community deployment of rapid access systems has been
evolving since the late 1960s, when portable defibrillators
initially became available. The first systems were fire
department-based paramedical programs, and were fol-
lowed years later by the placement of automated external
defibrillators (AEDs) in the hands of non-conventional
trained responders, such as security guards, police, and flight
attendants (8–15). Most recently, defibrillators were made
available to minimally trained or untrained lay responders in
public locations such as airports, commercial aircraft, super-
markets, stadiums, and hospitals (14–17), and have also
been suggested for private residences or neighborhoods (18).
Although survival rates from out-of-hospital cardiac ar-
rest remain far lower than desirable, the various out-of-
hospital response strategies have improved the survival rates,
largely based on more rapid response times. Those settings
and strategies that provide response times from witnessed
onset to initial defibrillation of less than 2 to 3 min can
provide survival outcomes hovering about 50% (16); but
rates fall sharply with each passing minute thereafter. By 4
to 5 min, survival is 25% or less, and less than 10% after 10
min (19). As a consequence, despite the apparent value of
conventional emergency medical systems and other vehicle-
based systems such as police responders, additional public
access systems are anticipated to provide even faster access
to defibrillation. Such systems are being deployed and tested
(20,21). Each has potential or demonstrates added benefit
to survival rates.
AEDs AT SITES OF TRAINING AND COMPETITION
Among young athletes, cardiac arrests generally occur during
or shortly after intense training sessions or competition. Al-
though the incidence of cardiac arrest is extremely low (ap-
proximately 1% of that reported in middle-age and older adult
populations), the value of prompt and successful resuscitation
and long-term survival is enhanced by the potential of ex-
tended life over many decades (i.e., much longer than is the
case for older adults, among whom the extent of underlying
disease results in substantial risk over shorter time periods).
Thus, it is considered reasonable to have an AED available for
use at educational facilities, training centers, and sports arenas
and stadiums, in addition to trained responders among the staff
at each (5,21). The AEDs should be deployed in a distribution
that can achieve an anticipated response time of 5 min or less
(22). When the time from loss of consciousness to availability
of an AED is 5 min or longer, 30 to 60 s of CPR prior to the
first attempt to defibrillate has been shown to provide a survival
benefit (23).
Although there are only anecdotal observations supporting
the feasibility and impact of this strategy, the rationale is clear
and should be promoted. In addition, it should be recognized
that the availability of AEDs during competitive sporting
events also provides the potential for life-saving support to
spectators and other bystanders. Nonetheless, the availability of
an AED at a sporting event should not be construed as
absolute protection against a fatal outcome from a cardiac
arrest. Neither should it supersede restrictions against partici-
pation in competitive sports, based upon underlying cardiac
abnormalities, as defined in this document.
Recommendations:
1. The AEDs should be available at educational facili-
ties that have competitive athletic programs (includ-
ing intramural sports and conditioning classes), sta-
diums, arenas, and training sites, with trained
responders identified among the permanent staff.
Devices should be deployed so as to provide a
response time of less than 5 min.
2. The initial response to a suspected or identified cardiac
arrest should be to contact emergency medical services
(e.g., 9-1-1), followed immediately by, or concomitant
with, initiating CPR and deploying the AED.
doi:10.1016/j.jacc.2005.02.017
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GENERAL CONSIDERATIONS
Sudden and unexpected deaths of young athletes are most
frequently the consequence of unsuspected cardiovascular
diseases (1). However, participants in organized sports are also
subject to another risk for sudden death that occurs in the
absence of cardiovascular disease—namely, blunt, non-
penetrating, and usually innocent-appearing chest blows, trig-
gering ventricular fibrillation unassociated with structural
damage to the ribs, sternum, or heart itself (commotio cordis)
(2,3). Although the precise incidence during competitive
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